Oramed Pharmaceuticals Inc. (ORMP) News

Oramed Pharmaceuticals Inc. (ORMP)

Today's Latest Price: $3.57 USD

0.05 (1.42%)

Updated Jul 6 11:59am

Add ORMP to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 336 in Biotech

See all "A" rated Strong Buy stocks

Filter ORMP News Items

ORMP News Results

Event/TimeSymbolCompanyNews DetailStartEndChangePOWR Rating
Loading, please wait...

Latest ORMP News From Around the Web

Below are the latest news stories about Oramed Pharmaceuticals Inc that investors may wish to consider to help them evaluate ORMP as an investment opportunity.

ORMP: Positive Takeaways of Preliminary NASH Study Findings

By M. Marin NASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT Oramed Pharmaceuticals Inc. (NASDAQ:ORMP), a clinical-stage pharmaceutical company with a proprietary oral protein delivery platform technology, presented preliminary data findings from its NASH study at the American Diabetes Association Scientific Session 2020 this week. The company announced that its NASH study has shown ORMD-0801 to be

Yahoo | June 19, 2020

Oramed Announces Positive Initial Clinical Trial Results for Treatment of NASH With Oral Insulin

NEW YORK, June 15, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that its pilot study of its oral insulin candidate ORMD-0801…

PR Newswire | June 15, 2020

Newsflash: Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Analysts Have Been Trimming Their Revenue Forecasts

Today is shaping up negative for Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) shareholders, with the analysts delivering...

Yahoo | June 9, 2020

Oramed Pharmaceuticals Inc. (ORMP): Are Hedge Funds Right About This Stock?

In this article we will take a look at whether hedge funds think Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, unconventional data sources, expert networks, and get tips […]

Yahoo | June 4, 2020

Oramed Pharmaceuticals to Present at the 80th American Diabetes Association Scientific Session, to be Held Virtually This Year in June

NEW YORK, May 5, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced it will present during the 80th American Diabetes Association…

PR Newswire | May 5, 2020

Will Oramed Pharmaceuticals (NASDAQ:ORMP) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Yahoo | May 5, 2020

ORMP: Second quarter financial results; Strengthens Advisory Board; Positive EoP2 meeting with the FDA

By Anita Dushyanth, PhD NASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT Financial Update Oramed (NASDAQ:ORMP) reported second quarter financial results on 6th April, 2020 and provided a business update. The company reported revenues of $674k for the quarter. These revenues are related to the license agreement with Hefei Tianhui Incubator of Technologies Co., Ltd. (HTIT) signed in 2015 and are

Yahoo | April 14, 2020

Oramed Patent in Canada Allowed for Oral Delivery of Proteins

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Canadian Patent Office has indicated its intent to grant the Company a patent for its invention titled "Methods and Compositions for Oral Administration of Proteins."

Yahoo | April 7, 2020

Oramed Pharmaceuticals Issues CEO Shareholder Letter Providing Business Update Amid COVID-19

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, is pleased to provide the following Letter to Shareholders from Chief Executive Officer Nadav Kidron.

Yahoo | April 1, 2020

Does Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Have A Particularly Volatile Share Price?

Anyone researching Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) might want to consider the historical volatility of the...

Yahoo | March 30, 2020



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.764 seconds.